A detailed history of Casdin Capital, LLC transactions in 2seventy Bio, Inc. stock. As of the latest transaction made, Casdin Capital, LLC holds 2,000,000 shares of TSVT stock, worth $6.28 Million. This represents 0.73% of its overall portfolio holdings.

Number of Shares
2,000,000
Previous 2,000,000 -0.0%
Holding current value
$6.28 Million
Previous $7.7 Million 22.6%
% of portfolio
0.73%
Previous 0.66%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$3.09 - $6.0 $2.53 Million - $4.9 Million
817,377 Added 69.12%
2,000,000 $10.7 Million
Q4 2023

Feb 14, 2024

SELL
$1.57 - $4.58 $1.32 Million - $3.85 Million
-841,290 Reduced 41.57%
1,182,623 $5.05 Million
Q1 2023

May 15, 2023

BUY
$9.21 - $14.98 $1.6 Million - $2.61 Million
173,913 Added 9.4%
2,023,913 $20.6 Million
Q4 2022

Feb 14, 2023

BUY
$8.57 - $17.0 $10.6 Million - $21 Million
1,235,246 Added 200.93%
1,850,000 $17.3 Million
Q1 2022

May 16, 2022

BUY
$11.67 - $26.72 $7.17 Million - $16.4 Million
614,754 New
614,754 $10.5 Million

Others Institutions Holding TSVT

About 2seventy bio, Inc.


  • Ticker TSVT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 37,873,600
  • Market Cap $119M
  • Description
  • 2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. 2seventy bio, Inc. has a col...
More about TSVT
Track This Portfolio

Track Casdin Capital, LLC Portfolio

Follow Casdin Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Casdin Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Casdin Capital, LLC with notifications on news.